Edwards Lifesciences Corporation
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $583.6M | $569.5M | $494.9M | $811.1M | $389.1M | $291.5M | $236.7M | $218.0M |
| Depreciation & Amortization | $81.9M | $71.2M | $65.8M | $68.6M | $62.9M | $53.7M | $58.0M | $56.5M |
| Depreciation | $74.1M | $63.6M | $58.7M | $57.5M | $53.1M | $44.0M | $44.0M | $40.0M |
| Amortization | $7.8M | $7.6M | $7.1M | $8.4M | $9.9M | $9.7M | $14.1M | $16.6M |
| Stock-Based Compensation | $61.6M | $56.9M | $49.9M | $48.3M | $47.4M | $42.1M | $35.0M | $29.3M |
| Net Cash from Operating Activities | $1.00B | $704.4M | $549.7M | $1.02B | $472.7M | $362.1M | $308.2M | $251.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $168.1M | $176.1M | $102.7M | $82.9M | $109.0M | $109.0M | $76.6M | $61.8M |
| Business Acquisitions | $192.9M | $0 | $331.6M | $15.0M | $0 | $36.6M | $42.6M | — |
| Net Cash from Investing Activities | $-647.2M | $-211.7M | $-316.1M | — | — | — | — | $-61.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $763.3M | $662.3M | $280.1M | $300.9M | $496.9M | $344.1M | $303.4M | $200.0M |
| Net Cash from Financing Activities | $-473.2M | $-268.5M | $-158.6M | — | — | — | — | $-103.9M |
| Net Change in Cash | $-111.8M | $211.7M | $64.6M | $233.4M | $109.5M | $139.7M | $-224.9M | $62.0M |
| Free Cash Flow | $832.6M | $528.3M | $447.0M | $939.4M | $363.7M | $253.1M | $231.6M | $189.6M |